PATIENTS - CLINICAL APPROACH
Healthy Volunteers
The first clinical trial with PST-674 will be a Phase 1 study to test tolerability in healthy volunteers.
Proof-of-Concept
The PoC study will be a Phase 1b/2a study in individuals with Down syndrome and dementia. Since there is a close link between DYRK1A and dementia in Down syndrome, this is an ideal group to demonstrate the effect of PST-674 for the treatment of dementia.
Dementia in Alzheimer´s and Parkinson´s disease
Since DYRK1A also plays a central role in other forms of dementia, further clinical trials will also include Alzheimer’s disease in the general population and dementia associated with Parkinson’s disease. Testing of PST-674 in large patient groups (Phase 3) will be done in collaboration with a partner.